Finland-based DelSiTech has signed a world-wide, exclusive license agreement with Innovare R&D, a Mexico-based pharma company, it was reported yesterday.
The contract has been signed for the use of the former's Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy.
According to the terms of the agreement, Innovare will use DelSiTech's technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1. DelSiTech is entitled to receive an upfront payment, milestone payments and royalties on development, commercialisation and sales of the Silica Matrix formulated T1144 drug product. Financial details of the deal were not revealed.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results